Patents by Inventor Sheryl Jeanne Hays

Sheryl Jeanne Hays has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
    Patent number: 6632831
    Abstract: The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: October 14, 2003
    Assignee: Pfizer Inc.
    Inventors: Sheryl Jeanne Hays, Lain-Yen Hu, Huangshu Lei, Jeffrey David Scholten, David Juergen Wustrow
  • BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
    Publication number: 20030162779
    Abstract: The invention relates to BCAT inhibitors and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, neuropathic pain, Parkinson's disease, diabetic retinopathy, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.
    Type: Application
    Filed: November 26, 2002
    Publication date: August 28, 2003
    Inventors: Sheryl Jeanne Hays, Lain-Yen Hu, Huangshu Lei, Jeffrey David Scholten, David Juergen Wustrow
  • Naphthylazo inhibition of amyloidosis
    Patent number: 6017913
    Abstract: Amyloid aggregation in animals is inhibited by administering a naphthylazo compound of the formula ##STR1## wherein R.sup.1 and R.sup.2 are hydrogen, alkyl, substituted alkyl, or complete a heterocyclic ring, R.sup.3 is hydrogen or alkyl, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 are substituent groups. The compounds are especially useful in preventing and treating Alzheimer's disease.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: January 25, 2000
    Assignee: Warner-Lambert Company
    Inventors: Sheryl Jeanne Hays, Harry LeVine, III, Jeffery David Scholten
  • Inhibition of amyloidosis by 9-acridinones
    Patent number: 5972956
    Abstract: Amyloid aggregation in animals is inhibited by administering a 9-acridinone compound of formula I, defined herein. The compounds are especially useful in preventing and treating Alzheimer's disease.
    Type: Grant
    Filed: April 29, 1998
    Date of Patent: October 26, 1999
    Assignee: Warner-Lambert Company
    Inventors: Sheryl Jeanne Hays, Harry LeVine, III, Jeffery David Scholten
  • Naphthylazo inhibition of amyloidosis
    Patent number: 5955472
    Abstract: Amyloid aggregation in animals is inhibited by administering a naphthylazo compound of formula (I), wherein R1 and R2 are hydrogen, alkyl, substituted alkyl, or complete a heterocyclic ring, R3 is hydrogen or alkyl, R4, R5, R6, and R7 are substitutent groups. The compounds are especially useful in preventing and treating Alzheimer's disease.
    Type: Grant
    Filed: April 29, 1998
    Date of Patent: September 21, 1999
    Assignee: Warner-Lambert Company
    Inventors: Sheryl Jeanne Hays, Harry LeVine, III, Jeffery David Scholten
  • Hydroxamate inhibitors of interleukin-1.beta. converting enzyme
    Patent number: 5919790
    Abstract: The present invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme that have the Formula II ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock, reperfusion injury, Alzheimer's disease, shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1.beta. converting enzyme.
    Type: Grant
    Filed: October 2, 1997
    Date of Patent: July 6, 1999
    Assignees: Warner-Lambert Company, BASF Aktiengesellsschaft
    Inventors: Hamish John Allen, Kenneth Dale Brady, Bradley William Caprathe, Paul Galatsis, John Lodge Gilmore, Sheryl Jeanne Hays, Robert Vincent Talanian, Nigel Walker, Joseph Scott Warmus
  • 2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease for the treatment of inflammatory processes
    Patent number: 5652237
    Abstract: This invention concerns certain 2-substituted-3,1-benzoxazin-4-ones and benzthiazinones as complement Clr protease inhibitors and antiinflammatory agents, pharmaceutical compositions containing them, methods of using them, and processes for their preparation.
    Type: Grant
    Filed: August 10, 1995
    Date of Patent: July 29, 1997
    Assignee: Warner-Lambert Company
    Inventors: Corinne Elizabeth Augelli-Szafran, Bradley William Caprathe, John Lodge Gilmore, Sheryl Jeanne Hays, Juan Carlos Jaen, Jan Ruth Penvose-Yi